Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
12.75(c) 11.76(c) 11.7(c) 11.46(c) 10.3(c) Last
2 386 583 2 901 314 4 037 117 1 918 483 2 656 428 Volume
-1.85% -7.76% -0.51% -2.05% -10.12% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 78,3 M - -
Net income 2021 -534 M - -
Net Debt 2021 336 M - -
P/E ratio 2021 -2,77x
Yield 2021 -
Sales 2022 83,6 M - -
Net income 2022 -583 M - -
Net Debt 2022 896 M - -
P/E ratio 2022 -2,56x
Yield 2022 -
Capitalization 1 516 M 1 516 M -
EV / Sales 2021 23,7x
EV / Sales 2022 28,8x
Nbr of Employees 391
Free-Float -
More Financials
Company
BridgeBio Pharma, Inc. is a United States-based company, The Company discovers and develops medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561,... 
Sector
Pharmaceuticals
Calendar
03/07Earnings Release
More about the company
Ratings of BridgeBio Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BRIDGEBIO PHARMA, INC.
01/20BRIDGEBIO PHARMA : Corporate Presentation January 2022
PU
01/17SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bridg..
PR
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
DJ
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
MT
01/13BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially B..
GL
01/10BRIDGEBIO PHARMA : Corporate Presentation January 2022
PU
01/06SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bridg..
PR
01/05UBS Adjusts BridgeBio Pharma PT to $30 From $80, Maintains Buy Rating
MT
01/05BRIDGEBIO PHARMA : Corporate Presentation January 2022
PU
01/04INSIDER BUY : Bridgebio Pharma
MT
2021Alnylam Pharmaceuticals' Onpattro in 'Relatively Strong Position' to Succeed Despite Br..
MT
2021HC Wainwright Adjusts BridgeBio Pharma's Price Target to $24 From $88, Reiterates Buy R..
MT
2021Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $24 From $86, Reiterates Buy ..
MT
2021US Stocks Gain for 4th Straight Session, S&P 500 Hits Another Record
MT
2021US Stocks Start Week Broadly Higher With S&P 500 Hitting Record High
MT
More news
News in other languages on BRIDGEBIO PHARMA, INC.
01/13BridgeBio Pharma et Amgen s'associent pour évaluer un traitement combiné contre les tum..
01/04ACHAT D'INITIÉS : Bridgebio Pharma
2021Selon Oppenheimer, l'Onpattro d'Alnylam Pharmaceuticals est en " position relativement ..
2021Les actions américaines progressent pour la quatrième séance consécutive, le S&P 500 at..
2021Les actions américaines commencent la semaine en hausse, le S&P 500 atteignant un nivea..
More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 10,30 $
Average target price 27,40 $
Spread / Average Target 166%
EPS Revisions
Managers and Directors
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BRIDGEBIO PHARMA, INC.-38.25%1 516
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356